Table 1 Demographic and clinical characteristics of the discovery cohort
From: Circular RNAs to predict clinical outcome after cardiac arrest
Characteristics | Neurological outcome | p-value | |
|---|---|---|---|
CPC1 (n = 23) | CPC5 (n = 23) | ||
Age, years | 61 (41–80) | 74 (53- 90) | 0.002 |
Sex | |||
 Male | 20 (87%) | 19 (82.6%) | 1 |
 Female | 3 (13%) | 4 (17.4%) | |
Co-morbidities | |||
 Hypertension | 7 (30.4%) | 11 (47.8%) | 0.19 |
 Diabetes mellitus | 2 (8.7%) | 5 (21.7%) | 1 |
 Known IHD | 3 (13%) | 12 (52.2%) | 0.093 |
 Previous MI | 2 (8.7%) | 9 (39.1%) | 0.502 |
 Heart failure | 1 (4.3%) | 2 (8.7%) | 1 |
 COPD | 1 (4.3%) | 4 (17.4%) | 0.174 |
 Previous cerebral stroke | 1 (4.3%) | 3 (13%) | 1 |
First monitored rhythm | |||
 VF or non-perfusing VT | 22 (95.7%) | 18 (78.3%) | 0.865 |
 Asystole or PEA | 1 (4.3%) | 4 (17.4%) | |
 ROSC after bystander defibrillation | – | 1 (4.3%) | |
Witnessed arrest | 20 (87%) | 20 (87%) | 0.356 |
Bystander CPR | 16 (69.6%) | 17 (74%) | 0.318 |
Time from CA to ROSC, min | 20 (8–45) | 29 (11–65) | 0.02 |
Initial serum lactate (mmol/l) | 3.2 (0–17) | 4.7 (0–16) | 0.244 |
NSE 48 h after ROSC (ng/ml) | 15 (6.6–49.2) | 62.1 (8.8–291.2) | < 0.001 |
Shock on admission | 2 (8.7%) | 8 (34.8%) | 0.111 |